Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Schering Leader Outlines Plans To Integrate Chinese Scientists Into Worldwide Research, Exchanges: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Chris Lee, the Asia-Pacific regional head for Bayer Schering Pharma, recently discussed with the China Bureau of PharmAsia News the German-headquartered outfit's plans to expand exchanges between scientists at its new R&D center in Beijing and other Bayer research outposts, and projections that China will be a global growth driver into the future (PharmAsia News, Feb.19, 2009).

You may also be interested in...



Bayer Shifting Further To Emerging Markets Including China

Already a big player in the world's largest pharmemerging market, China, Bayer is plunging deeper and reallocating more resources in capital investment and manpower to emerging markets

Bayer Shifting Further To Emerging Markets Including China

Already a big player in the world's largest pharmemerging market, China, Bayer is plunging deeper and reallocating more resources in capital investment and manpower to emerging markets

As Financial Turmoil Engulfs West, Germany’s Bayer Looks East To Form R&D Center In Rising China

BEIJING - German pharmaceutical powerhouse Bayer Schering is engineering an alliance with Chinese scientists to create a global research and development center in Beijing, according to senior Bayer executives

Latest News
UsernamePublicRestriction

Register

SC074013

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel